Search results for "SCR"

showing 10 items of 11806 documents

Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.

2021

Abstract Aims Epidermal growth factor receptor (EGFR) is not only involved in carcinogenesis, but also in chemoresistance. We characterized U87.MGΔEGFR glioblastoma cells with constitutively active EGFR due to deletion at the ligand binding domain in terms of gene expression profiling and chromosomal aberrations. Wild-type U87.MG cells served as control. Materials and methods RNA sequencing and network analyses (Ingenuity Pathway Analysis) were performed to identify novel drug resistance mechanisms related to expression of mutation activated EGFR. Chromosomal aberrations were characterized by multicolor fluorescence in situ hybridization (mFISH) and array comparative genomic hybridization (…

0301 basic medicineDown-RegulationBiologymedicine.disease_cause030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyTranscriptome03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansGene Regulatory NetworksProtein Interaction MapsGeneral Pharmacology Toxicology and PharmaceuticsGeneTranscription factorMetaphaseChromosome AberrationsMutationmedicine.diagnostic_testBrain NeoplasmsGene Expression ProfilingGeneral MedicineGenomicsUp-RegulationGene expression profilingErbB ReceptorsGene Expression Regulation Neoplastic030104 developmental biologyDrug Resistance NeoplasmMutationCancer researchCarcinogenesisGlioblastomaTranscriptomeComparative genomic hybridizationFluorescence in situ hybridizationSignal TransductionLife sciences
researchProduct

Fishing anti-inflammatories from known drugs: In silico repurposing, design, synthesis and biological evaluation of bisacodyl analogues

2017

Herein is described in silico repositioning, design, synthesis, biological evaluation and structure-activity relationship (SAR) of an original class of anti-inflammatory agents based on a polyaromatic pharmacophore structurally related to bisacodyl (BSL) drug used in therapeutic as laxative. We describe the potential of TOMOCOMD-CARDD methods to find out new anti-inflammatory drug-like agents from a diverse series of compounds using the total and local atom based bilinear indices as molecular descriptors. The models obtained were validated by biological studies, identifying BSL as the first anti-inflammatory lead-like using in silico repurposing from commercially available drugs. Several bi…

0301 basic medicineDrugBisacodylAnti-inflammatory databasemedia_common.quotation_subjectIn silico[CHIM.THER]Chemical Sciences/Medicinal Chemistry03 medical and health sciencesIn vivoMolecular descriptorDrug DiscoveryDiarylmethylpyridinesmedicine[CHIM.CRIS]Chemical Sciences/CristallographyBisacodylRepurposingComputingMilieux_MISCELLANEOUSmedia_commonAnti-inflammatory assayChemistry[CHIM.ORGA]Chemical Sciences/Organic chemistryGeneral MedicineCombinatorial chemistry[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]3. Good health030104 developmental biologyMechanism of actionAtom-based bilinear indicesmedicine.symptomPharmacophoreTOMOCOMD-CARDD SoftwareRepurposingmedicine.drug
researchProduct

Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury

2017

Drug-induced liver injury (DILI) has a considerable impact on human health and is a major challenge in drug safety assessments. DILI is a frequent cause of liver injury and a leading reason for post-approval drug regulatory actions. Considerable variations in the expression levels of both cytochrome P450 (CYP) and conjugating enzymes have been described in humans, which could be responsible for increased susceptibility to DILI in some individuals. We herein explored the feasibility of the combined use of HepG2 cells co-transduced with multiple adenoviruses that encode drug-metabolising enzymes, and a high-content screening assay to evaluate metabolism-dependent drug toxicity and to identify…

0301 basic medicineDrugCYP2B6Drug-induced liver injuryHealth Toxicology and Mutagenesismedia_common.quotation_subjectPopulationDrug Evaluation PreclinicalPharmacologyToxicologyHepatotoxicity mechanismsGene Expression Regulation EnzymologicOrgan Toxicity and MechanismsAdenoviridae03 medical and health sciences0302 clinical medicineCYPToxicity TestsHumansCytochrome P450 Family 2educationmedia_commonMembrane Potential Mitochondrialeducation.field_of_studyCYP3A4biologyCytochrome P450IdiosyncrasyHep G2 CellsGeneral MedicineCYP2E1Recombinant ProteinsHigh-Throughput Screening Assays030104 developmental biology030220 oncology & carcinogenesisInactivation MetabolicToxicityCell modelbiology.proteinChemical and Drug Induced Liver InjuryReactive Oxygen SpeciesDrug metabolism
researchProduct

Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis

2016

Only a few in vitro assays have been proposed to evaluate the steatotic potential of new drugs. The present study examines the utility of HepaRG cells as a cell-based assay system for screening drug-induced liver steatosis. A high-content screening assay was run to evaluate multiple toxicity-related cell parameters in HepaRG cells exposed to 28 compounds, including drugs reported to cause steatosis through different mechanisms and non-steatotic compounds. Lipid content was the most sensitive parameter for all the steatotic drugs, whereas no effects on lipid levels were produced by non-steatotic compounds. Apart from fat accumulation, increased ROS production and altered mitochondrial membra…

0301 basic medicineDrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectCellDrug Evaluation PreclinicalBiologyPharmacologyToxicology03 medical and health sciencesCell Line TumormedicineHumansTranscription factormedia_commonPharmacologyMembrane potentialFatty liverIn vitro toxicologyLipid metabolismLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologymedicine.anatomical_structureSteatosisToxicology and Applied Pharmacology
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

<b><i>Objective:</i></b> Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.<b><i></i></b>The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). <b><i>Materials and Methods:</i></b> We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct

A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.

2017

Human hepatic cells have been used for drug safety risk evaluations throughout early development phases. They provide rapid, cost-effective early feedback to identify drug candidates with potential hepatotoxicity. This unit presents a cell-based assay to evaluate the risk of liver damage associated with steatogenic drugs. Detailed protocols for cell exposure to test compounds and for the assessment of steatosis-related cell parameters (intracellular lipid content, reactive oxygen species production, mitochondrial impairment, and cell death) are provided. A few representative results that illustrate the utility of this procedure for the screening of drug-induced steatosis are shown. © 2017 b…

0301 basic medicineDrugProgrammed cell deathmedia_common.quotation_subjectCellMitochondria LiverBiologyToxicology03 medical and health sciencesmedicineHumansCells Culturedmedia_commonchemistry.chemical_classificationReactive oxygen speciesCell Deathmedicine.diseaseLipid MetabolismFatty Liver030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryLiverHigh-content screeningCancer researchHepatic stellate cellHepatocytesSteatosisChemical and Drug Induced Liver InjuryReactive Oxygen SpeciesIntracellularCurrent protocols in toxicologyLiterature Cited
researchProduct

Myotonic dystrophy type 1 drug development: A pipeline toward the market

2021

Highlights • Myotonic dystrophy, a neuromuscular disease, affects at least around half a million people worldwide. • Close to two dozen preclinical and clinical drug development programs active. • Drugs encompass new chemical entities, repurposing, oligonucleotide, and gene therapy. • Tideglusib, mexiletine, and metformin are close to reaching marketing authorization.

0301 basic medicineDrugmedia_common.quotation_subjectMyotonic dystrophyDiseaseBioinformaticsMarketing authorizationMyotonic dystrophy03 medical and health sciences0302 clinical medicineGene therapyDrug DevelopmentDrug DiscoveryMedicineAnimalsHumansAntisense oligonucleotideRepurposingmedia_commonPharmacologybusiness.industryRepurposing drugmedicine.diseaseClinical trialClinical trialDrug repositioning030104 developmental biologyDrug development030220 oncology & carcinogenesisbusinessPost-Screen (Grey)Drug Discovery Today
researchProduct

Beneficial Role of Exercise in the Modulation of

2021

Duchenne muscular dystrophy (DMD) is an X-linked recessive progressive lethal disorder caused by the lack of dystrophin, which determines myofibers mechanical instability, oxidative stress, inflammation, and susceptibility to contraction-induced injuries. Unfortunately, at present, there is no efficient therapy for DMD. Beyond several promising gene- and stem cells-based strategies under investigation, physical activity may represent a valid noninvasive therapeutic approach to slow down the progression of the pathology. However, ethical issues, the limited number of studies in humans and the lack of consistency of the investigated training interventions generate loss of consensus regarding …

0301 basic medicineDuchenne muscular dystrophyPhysiologyDuchenne muscular dystrophyClinical BiochemistryInflammationReviewBioinformaticsmedicine.disease_causeBiochemistrySettore BIO/09 - FisiologiaMuscle hypertrophy03 medical and health sciencesTherapeutic approach0302 clinical medicineFibrosismedicineTrainingMuscle inflammationVoluntary exerciseMolecular BiologySwimmingbiologybusiness.industrylcsh:RM1-950ROSCell Biologymedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyantioxidantsTreadmill runningbiology.proteinmedicine.symptomAntioxidantDystrophinExercise prescriptionbusiness030217 neurology & neurosurgeryOxidative stressAntioxidants (Basel, Switzerland)
researchProduct

Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming.

2016

During the process of reprogramming to induced pluripotent stem (iPS) cells, somatic cells switch from oxidative to glycolytic metabolism, a transition associated with profound mitochondrial reorganization. Neither the importance of mitochondrial remodelling for cell reprogramming, nor the molecular mechanisms controlling this process are well understood. Here, we show that an early wave of mitochondrial fragmentation occurs upon expression of reprogramming factors. Reprogramming-induced mitochondrial fission is associated with a minor decrease in mitochondrial mass but not with mitophagy. The pro-fission factor Drp1 is phosphorylated early in reprogramming, and its knockdown and inhibition…

0301 basic medicineDynaminsSomatic cellMAP Kinase Signaling SystemScienceCèl·lulesCellInduced Pluripotent Stem CellsKruppel-Like Transcription FactorsGeneral Physics and AstronomyBiologyMitochondrionMitochondrial DynamicsGeneral Biochemistry Genetics and Molecular BiologyMitocondrisArticleCell LineProto-Oncogene Proteins c-myc03 medical and health sciencesKruppel-Like Factor 4MiceMitophagymedicineAnimalsPhosphorylationInduced pluripotent stem cellGeneticsMultidisciplinarySOXB1 Transcription FactorsQGeneral ChemistryCellular ReprogrammingCell biologyMitochondria030104 developmental biologymedicine.anatomical_structurePhosphorylationMitochondrial fissionReprogrammingOctamer Transcription Factor-3Nature communications
researchProduct

Current state of genomic policies in healthcare among EU member states: results of a survey of chief medical officers

2016

Abstract Background A need for a governance of genomics in healthcare among European Union (EU) countries arose during an international meeting of experts on public health genomics (PHG). We have conducted a survey on existing national genomic policies in healthcare among Chief Medical Officers (CMOs) of the 28 EU member states, plus Norway. Methods A questionnaire was sent to CMOs after a meeting on the policy implications of PHG held during the Italian presidency of the Council of EU in 2014. The survey was closed in November 2015. Results CMOs response rate was 65.5% (19/29). Twelve (63.2%) reported that their countries had a policy for genomics in healthcare in place, and 15 (78.9%) rep…

0301 basic medicineEconomic growthPresidencyHealth Personnelsurvey.Harmonization030105 genetics & hereditySettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesEnvironmental healthHealth careHumansmedia_common.cataloged_instanceMedicineEuropean Union030212 general & internal medicineEuropean unionSurveySettore MED/42 - IGIENE GENERALE E APPLICATAmedia_common...Public Health; genomics and health care; Public Health Genomics; policy; survey.Public health genomicsNorwaybusiness.industryCorporate governanceHealthcarePublic Health Environmental and Occupational HealthHealth technologyGenomicsgenetic screeningPublic health genomicMiscellaneous3. Good healthpublic health medicinePublic Healthgenomics and health careWorking groupbusinessDelivery of Health Carepolicy
researchProduct